Key Points
- CEO Mark Okey Decker Jr. bought 6,875 shares at an average price of $35.92, investing approximately $246,950 and increasing his direct ownership by 10.06% to 75,199 shares.
- Global Medical REIT reported quarterly EPS of $4.78, far exceeding the $0.83 consensus estimate, on revenue of $39.75 million. The company also posted a 36.82% net margin and 13.74% return on equity.
- Analyst sentiment remains mixed, with a consensus “Hold” rating and an average price target of $40.25 versus a recent share price of $36.52. Investors should also note the company’s elevated leverage, reflected in a 1.68 debt-to-equity ratio.
Global Medical REIT Inc. (NYSE:XRN - Get Free Report) CEO Mark Okey Decker, Jr. acquired 6,875 shares of the company's stock in a transaction that occurred on Tuesday, August 11th. The stock was purchased at an average cost of $35.92 per share, with a total value of $246,950.00. Following the completion of the purchase, the chief executive officer directly owned 75,199 shares in the company, valued at $2,701,148.08. This represents a 10.06% increase in their ownership of the stock. The acquisition was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink.
Global Medical REIT Stock Performance
Shares of XRN stock opened at $36.52 on Friday. The stock has a fifty day moving average price of $36.59 and a 200 day moving average price of $35.80. The company has a debt-to-equity ratio of 1.68, a quick ratio of 0.68 and a current ratio of 0.68. The stock has a market cap of $483.43 million, a PE ratio of 9.82 and a beta of 1.09. Global Medical REIT Inc. has a 1 year low of $29.05 and a 1 year high of $39.93.
Global Medical REIT (NYSE:XRN - Get Free Report) last posted its earnings results on Wednesday, August 5th. The company reported $4.78 earnings per share for the quarter, beating the consensus estimate of $0.83 by $3.95. Global Medical REIT had a return on equity of 13.74% and a net margin of 36.82%.The company had revenue of $39.75 million for the quarter. Sell-side analysts forecast that Global Medical REIT Inc. will post 3.06 earnings per share for the current fiscal year.
Institutional Inflows and Outflows
Several institutional investors have recently added to or reduced their stakes in XRN. Caitong International Asset Management Co. Ltd lifted its holdings in Global Medical REIT by 1,001.4% in the 3rd quarter. Caitong International Asset Management Co. Ltd now owns 793 shares of the company's stock valued at $27,000 after purchasing an additional 721 shares in the last quarter. Fifth Third Bancorp lifted its stake in shares of Global Medical REIT by 35.3% during the fourth quarter. Fifth Third Bancorp now owns 1,417 shares of the company's stock valued at $48,000 after buying an additional 370 shares during the period. Tower Research Capital LLC TRC lifted its stake in shares of Global Medical REIT by 70.3% during the 2nd quarter. Tower Research Capital LLC TRC now owns 7,379 shares of the company's stock worth $51,000 after purchasing an additional 3,046 shares during the period. B. Riley Wealth Advisors Inc. purchased a new position in shares of Global Medical REIT during the 2nd quarter worth $78,000. Finally, Virtus Advisers LLC boosted its holdings in shares of Global Medical REIT by 46.5% during the fourth quarter. Virtus Advisers LLC now owns 2,418 shares of the company's stock worth $82,000 after purchasing an additional 768 shares during the last quarter. Institutional investors and hedge funds own 57.52% of the company's stock.
Global Medical REIT News Roundup
Here are the key news stories impacting Global Medical REIT this week:
- Positive Sentiment: Insiders purchased roughly $2.54 million of shares over August 10–12. CEO Mark Okey Decker, Jr. bought 15,425 shares in three transactions, COO Aaron Robert Roseth acquired 13,500 shares for approximately $495,855, and director Charles Fitzgerald purchased 41,600 shares worth about $1.49 million. The purchases increase management’s financial exposure to the company and may signal confidence in its outlook. SEC insider purchase filing
- Positive Sentiment: The company’s latest quarterly results were substantially above expectations, with earnings per share of $4.78 versus the $0.83 analyst consensus and revenue of $39.75 million. Global Medical REIT also reported a 36.82% net margin and 13.74% return on equity, providing fundamental support for the recent interest in the shares.
- Neutral Sentiment: Analyst sentiment remains mixed. The consensus rating is “Hold,” with two Buy, five Hold and one Sell rating; however, the average price target of $40.25 is above the stock’s recent trading range. Price targets include $42 from Citizens JMP and $38 from Compass Point.
- Neutral Sentiment: A recent article discusses the company’s transition and rebranding to Chiron Real Estate, which could affect how investors interpret the company’s identity and strategy. How Did Chiron Real Estate Emerge From the GMRE Rebrand?
- Negative Sentiment: Global Medical REIT carries elevated leverage, with a debt-to-equity ratio of 1.68, while its quick and current ratios are both 0.68. These figures could limit financial flexibility, particularly if interest rates remain high or property markets weaken.
Analysts Set New Price Targets
A number of equities analysts have issued reports on XRN shares. Wall Street Zen cut shares of Global Medical REIT from a "hold" rating to a "sell" rating in a research report on Saturday, May 9th. BMO Capital Markets increased their price target on shares of Global Medical REIT from $39.00 to $40.00 and gave the company a "market perform" rating in a research report on Monday, July 13th. Raymond James Financial assumed coverage on shares of Global Medical REIT in a research note on Wednesday, June 17th. They set a "market perform" rating for the company. Zacks Research upgraded Global Medical REIT to a "hold" rating in a research report on Wednesday, July 22nd. Finally, Citizens Jmp upped their target price on Global Medical REIT from $40.00 to $42.00 and gave the company a "market outperform" rating in a research note on Tuesday, May 26th. Two investment analysts have rated the stock with a Buy rating, five have given a Hold rating and one has issued a Sell rating to the company. According to MarketBeat.com, Global Medical REIT has an average rating of "Hold" and an average target price of $40.25.
Get Our Latest Stock Report on Global Medical REIT
About Global Medical REIT
(
Get Free Report)
Global Medical REIT (NYSE: GMRE) is a real estate investment trust focused on owning and managing healthcare-related properties across the United States. The company acquires, develops and leases a diversified portfolio of medical office buildings, outpatient facilities, long-term care centers and other specialized healthcare real estate. By concentrating on essential healthcare assets, Global Medical REIT seeks to generate stable, long-term rental income under triple-net and modified gross lease structures.
Since its incorporation in 2016 and initial public offering in 2017, the company has pursued an acquisitive growth strategy targeting markets with strong demographic trends and limited supply of modern medical facilities.
Read More
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
